Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
10/2007
10/03/2007CN101045724A Coupling method for preparing quinolone intermediate
10/03/2007CN100340554C Halogen substituted tetracyclic tetrahydrofuran derivatives
10/02/2007US7276608 3-(amino)sulfonylamino-substituted, e.g., N-(1,6-Dibenzyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide and N-(1-Benzyl-2-oxo-6-(thiophen-3-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide; eating, metabolic, obesity, cognitive, neurological, pain, inflammatory and psychiatric disorders
10/02/2007US7276606 Phenantridine analogues and uses thereof
10/02/2007US7276601 Method and preparing fused oxazinones
10/02/2007US7276531 G-lactam derivatives as prostaglandin agonists
10/02/2007US7276524 Compounds as antumor agents or immunosuppressants
10/02/2007US7276523 For therapy and prophylaxis of postmenopausal osteoporosis, estrogen-dependent breast cancer, and cardiovascular disease
10/02/2007US7276522 dextrorotatory and levo-rotatory enantiomers; specific to alpha2B adrenergic receptors
10/02/2007US7276521 Muscarinic acetylcholine receptor antagonists
10/02/2007US7276520 Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
10/02/2007US7276518 For therapy of neuropathic or chronic pain
10/02/2007US7276516 P-indolyl-, indazolyl- and pyrrolopyridyl-sulfonylbenzamides, e.g., N-(4-Fluoro-benzyl)-4-(3-phenyl-indole-1-sulfonyl)-benzamide; modulators of the Cannabinoid-1 receptor, especially useful for treating obesity
10/02/2007US7276510 Viricides; prevent reproduction of human T-Cell lymphocyte virus
10/02/2007US7276509 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic
10/02/2007US7276508 Indole derivatives useful for the treatment of CNS disorders
10/02/2007US7276501 6-(4-substituted-anilino)pyrimidine derivatives, method for preparation thereof and antiviral pharmaceutical composition comprising the same
10/02/2007US7276496 Cyclic malonamides as inhibitors of Aβ protein protection
10/02/2007US7276495 Substituted lactams as inhibitors of Aβ protein production
10/02/2007US7276348 Using benzodiazepine derivatives to treat and prevent defects in programed cell death, autoimmune, inflammatory and cell proliferative diseases
10/02/2007CA2413424C Substituted bicyclic derivatives for the treatment of abnormal cell growth
10/02/2007CA2401229C Aryl fused azapolycyclic compounds
10/02/2007CA2387357C Derivatives of pyrazolo[4,3-d]pyrimidin-7-ones which inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterase
10/02/2007CA2378613C Selective iglur5 receptor antagonists for the treatment of migraine
10/02/2007CA2349013C Intermediate for the synthesis of amlodipine, a process for the preparation thereof and corresponding use
10/02/2007CA2330756C Indole derivatives and their use for the treatment of malignant and other diseases based on pathological cell proliferation
10/02/2007CA2160912C 3-(het)arylcarboxylic acid derivatives, their preparation and intermediates for their preparation
10/02/2007CA2096407C Retroviral protease inhibitors
09/2007
09/27/2007WO2007109459A2 Pyridines and pyridine n-oxides as modulators of thrombin
09/27/2007WO2007109434A1 Besylate salt form of 1- (5-tert-butyl-2-p-t0lyl-2h-pyraz0l-3-yl) -3- (4- (6- (morpholin-4-yl-methyl) -pyrid in- 3 -yl) -naphthalen- 1-yl) -urea and polymorphs thereof
09/27/2007WO2007109238A1 Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity
09/27/2007WO2007109045A1 Heterocyclic organic compounds for the treatment of in particular melanoma
09/27/2007WO2007108936A2 N-substituted-azacyclylamines as histamine-3 antagonists
09/27/2007WO2007108743A2 Novel quinazolines as 5-ht6 modulators ii
09/27/2007WO2007107965A1 Cyclohexyl or piperidinyl carboxamide antibiotic derivatives
09/27/2007WO2007107772A1 Salts with crth2 antagonist activity
09/27/2007WO2007107550A1 Adamantane derivatives for the treatment of the metabolic syndrome
09/27/2007WO2007107545A1 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
09/27/2007WO2007107543A1 Inhibitors of the interaction between mdm2 and p53
09/27/2007WO2007107539A1 Compounds which potentiate ampa receptor and uses thereof in medicine
09/27/2007WO2007107499A1 Quinoline derivatives useful as pde4 inhibitors
09/27/2007WO2007107470A2 Pyrazoles as 11-beta-hsd-1
09/27/2007WO2007107373A1 Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
09/27/2007WO2007107319A1 Isolation, structure determination, synthesis and bioactivity of damipipecolin and damituricin
09/27/2007WO2007107298A1 Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
09/27/2007WO2007107245A1 Substituted 1-amino-4-phenyl-dihydroisoquinolines, method for the production thereof, use thereof as a medicament, and medicaments containing them
09/27/2007WO2007092065A9 Compounds and compositions as lxr modulators
09/27/2007WO2007085356A3 Insecticidal (heteroarylalkyl)alkane thio and oxo amine derivatives
09/27/2007WO2007025009A3 Indenoisoquinolinone analogs and methods of use thereof
09/27/2007WO2007022241A3 Novel high affinity quinoline-based kinase ligands
09/27/2007US20070225506 Bactericides; 2-[(1R)-1-methyl-2-trityl-2,3-dihydro-1H-5-isoindolyl]-1,3,6,2-dioxazaborocane.
09/27/2007US20070225502 Production of a precipitate of a 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole alkali metal salt by dissolving the compound in a first organic solvent, adding an alkali metal hydroxide, adding second organic solvent to reaction mixture; gastric acid secretion inhibitor
09/27/2007US20070225500 Process for the Preparation of Pyridin-2-Ylmethylsulphinyl-1H-Benzimidazol Compounds
09/27/2007US20070225372 Amides as Bace Inhibitors
09/27/2007US20070225352 methyl-[3-(2-nitro-phenylsulfanyl)-1-pyridin-2-ylmethyl-1H-indol-6-yl]-amine, possessing androgenic activity are useful in androgen-related treatments such as male hypogonadism, male and female hormone replacement therapy and male contraception
09/27/2007US20070225336 Anthropodicidal anthranilamides
09/27/2007US20070225335 Pyrazole Derivatives for Treating Condit Ions Mediated by Activation of the Adeno Sine A2B or A3 Receptor
09/27/2007US20070225333 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
09/27/2007US20070225329 Aryl aniline beta2 adrenergic receptor agonists
09/27/2007US20070225321 2,4-pyrimidinediamine compounds and their uses
09/27/2007US20070225319 Piperidinyl indole and tetrohydropyridinyl indole derivatives and methods of their use
09/27/2007US20070225308 2-Amino Quinazoline Derivative
09/27/2007US20070225307 C-met modulators and method of use
09/27/2007US20070225296 Arylalkylamine Compound and Process for Preparing the Same
09/27/2007US20070225294 2-[4-({[4-{[4-(4-acetylphenyl)-1-piperazinyl]methyl}-2-(4-fluorophenyl)-1,3-thiazol-5-yl]methyl}sulfanyl)-2-methylphenoxy]-2-methylpropanoic acid; dyslipidemia, syndrome X, hypercholesteremia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, and obesity
09/27/2007US20070225292 Therapeutic Compounds: Pyridine as Scaffold
09/27/2007US20070225291 Substituted Pyrazinone Compounds for the Treatment of Inflammation
09/27/2007US20070225287 Substituted Arylpyrazines
09/27/2007US20070225286 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs
09/27/2007US20070225272 CGRP receptor antagonists
09/27/2007US20070225269 Use of (3-(1-(3-Phenyl-Propenyl)-Piperidin-4-Yl)-2,3-Dihydro-Indol-1-Yl)-(Pyridin-4-Yl)-Methanonone Derivatives and Related Compounds as Insecticides
09/27/2007DE102006014324A1 Inhibitoren der löslichen Adenylatzklase Inhibitors of soluble Adenylatzklase
09/27/2007DE102006014320A1 Inhibitoren der löslichen Adenylatzklase Inhibitors of soluble Adenylatzklase
09/27/2007DE102006014319A1 Inhibitoren der löslichen Adenylatzyklase Inhibitors of soluble adenylate cyclase
09/27/2007DE102006012544A1 Substituierte 1-Amino 4-phenyl-dihydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament Substituted 1-amino 4-phenyl-dihydroisoquinolines, processes for their preparation, their use as a medicament, and medicament containing them
09/27/2007CA2647024A1 Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
09/27/2007CA2646958A1 Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity
09/27/2007CA2646588A1 Adamantane derivatives for the treatment of the metabolic syndrome
09/27/2007CA2646585A1 Compounds which potentiate ampa receptor and uses thereof in medicine
09/27/2007CA2646227A1 Substituted 1-amino-4-phenyl-dihydroisoquinolines, method for the production thereof, use thereof as a medicament, and medicaments containing them
09/27/2007CA2646002A1 Salts with crth2 antagonist activity
09/27/2007CA2645867A1 Substituted gamma lactams as prostaglandin ep2 agonists
09/27/2007CA2645731A1 N-substituted-azacyclylamines as histamine-3 antagonists
09/27/2007CA2645728A1 Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
09/27/2007CA2645546A1 Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
09/27/2007CA2645426A1 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses
09/27/2007CA2644649A1 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
09/27/2007CA2644643A1 Inhibitors of the interaction between mdm2 and p53
09/27/2007CA2644356A1 Heterocyclic organic compounds for the treatment of in particular melanoma
09/26/2007EP1837335A1 A method for the purification of Lansoprazole
09/26/2007EP1837332A1 Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
09/26/2007EP1836203A2 Heteroaryl substituted quinolin-4-ylamine analogues
09/26/2007EP1836194A1 4- (1h-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy
09/26/2007EP1836193A1 Unsymmetrical diazo compounds, compositions comprising same, dyeing method and device comprising said compositions
09/26/2007EP1836192A2 Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
09/26/2007EP1836191A1 Pyrazolylamino substituted quinazoles for the treatment of cancer
09/26/2007EP1836190A2 Preparation of pharmaceutical salts of piperazine compounds
09/26/2007EP1836189A1 Novel pyridine compounds
09/26/2007EP1836188A1 Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
09/26/2007EP1836187A1 1h-indole-3-carboxylic acid derivatives and their use as ppar agonists
1 ... 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 ... 1080